A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
OBJECTIVE: To explore adverse drug events (ADEs) associated with tirzepatide using real-world data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) database to guide its safe management. METHODS: ADE reports from th…
BACKGROUND: TikTok's MedTok is an interconnected network of patients, providers, and producers sharing knowledge and experiences of health-related topics. Awareness of popular content on weight loss medications can benefit health care professionals,…
AIMS: Peripheral artery disease (PAD) is a major diabetic complication and a leading cause of amputation. While GLP-1 receptor agonists (GLP-1 RAs) provide cardiovascular and limb protection, the impact of tirzepatide, a dual GLP-1/GIP receptor agoni…
AIMS: GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns have arisen about their potential link to thyroid cancer. This study investigates the asso…
AIM: To understand treatment patterns and effectiveness of tirzepatide among people without type 2 diabetes (T2D) in the US. METHODS: This retrospective, observational, descriptive study used the Healthcare Integrated Research Database (index date: f…
OBJECTIVE: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). DATA SOURCES: A literature review was conducted using the search terms,,,,, andon…
OBJECTIVE: Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes with tirzepatide by reproductive stage. METHODS:…
AIMS: This participant-level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions with tirzepatide treatment in participants with type 2 diabetes (T2D) from the SURPASS programme. MATERI…
BACKGROUND AND AIMS: Both semaglutide 2.4 mg and tirzepatide have been recently approved for chronic use in obesity. There is a lack of literature comparing the efficacy and safety of both these agents in people with obesity/overweight with or withou…
PURPOSE OF REVIEW: Researchers and clinicians have increasingly recognized the importance of investigating and considering sex differences in obesity treatment. In this narrative review, we first summarized sex differences in select obesity-related c…
INTRODUCTION: With recent clinical implementation of tirzepatide, patients with type 2 diabetes mellitus (T2DM) are transitioning from glucagon-like peptide 1 receptor agonists (GLP-1 RA) to a dual gastric inhibitory polypeptide (GIP)/GLP-1 RA-like t…
AIMS: This real-world study compared clinical outcomes between tirzepatide treatment and bariatric metabolic surgery (BMS) in adults with obesity. METHODS: This retrospective cohort study used the TriNetX network to identify adults with a body mass i…
INTRODUCTION: In SURMOUNT-2, a phase 3, randomized clinical trial, tirzepatide treatment resulted in clinically meaningful reduction in bodyweight among people with obesity or overweight and T2D. The current analysis evaluated the effects of tirzepat…
Tirzepatide, a dual glucagon-like peptide-1 receptor and gastric inhibitory peptide receptor agonist, is an effective treatment for type 2 diabetes mellitus and obesity, resulting in significant improvements in glycated hemoglobin levels and weight r…
Obesity is a growing global epidemic and a major risk factor for cardiovascular disease. However, previous weight loss interventions have largely failed to demonstrate consistent cardiovascular benefits. While lifestyle modifications remain the corne…
Hypertension is a frequent comorbidity of obesity that significantly and independently increases the risk of cardiovascular and renal events. Obesity-related hypertension is a major challenge to the healthcare system because of the rapid increase in…
IMPORTANCE: Medicare and many commercial insurers do not cover US Food and Drug Administration-approved weight management medications, such as incretin mimetics (semaglutide, tirzepatide, and liraglutide), bupropion-naltrexone, and phentermine-topira…
This case report highlights the multidisciplinary team (MDT) approach in managing a 49-year-old male with super-super obesity (initial Body Mass Index (BMI): 106.25 kg/m). Interventions included very-low-calorie-diet, tirzepatide treatment, and event…
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text].